With more than 30 years of healthcare and financial experience, he served as CEO of Equinox Funds and Chairman of Equinox Funds Trust, leading the firm’s growth from a commodity pool operator to an alternative investment asset manager with more than $2B in AUM. He has served in management roles with large, established companies, such as Bristol‑Myers Squibb, and fast‑growing, venture‑funded organizations, such as Beansprout Networks. He was Senior Managing Director with The Hermes Group, a merchant banking and corporate advisory firm as well as general manager and vice president of Quintiles (acquirer of Beansprout), a $2 billion pharmaceutical services firm. Mr Enck holds a BS degree in Natural Sciences from St. John's University, Collegeville, MN and an MBA in Management from the University of St. Thomas, St. Paul, MN. Mr Enck serves on the Board of Trustees of the Chi Chi Rodriguez Youth Foundation, and as Chairman of US Gold Opportunity Fund.

Professor Pantelis Georgiou is a co‑founder and CEO of ProtonDx, he currently holds the position of Professor of Biomedical Electronics at Imperial College London. Prof. Pantelis Georgiou graduated with a 1st Class Honours MEng Degree in Electrical and Electronic Engineering and PhD degree Imperial College London. He heads the Bio‑inspired Metabolic and Infection Technology Laboratory in the Centre for Bio‑Inspired Technology; a multi‑disciplinary group that invents, develops and demonstrates advanced micro‑devices to meet global challenges in biomedical science and healthcare. His research includes applications Lab‑on‑Chip technology for genomics and diagnostics targeted towards infectious disease and cancer. He has received the IET Mike Sergeant Medal, the IEEE Sensors Council Technical Achievement Award, and has been appointed as an IEEE Distinguished lecturer in circuits and systems. He has authored over 350 peer‑reviewed publications related to healthcare technology, and has successfully secured over £10 million in healthcare related research funding.

Assistant Professor Jesus Rodriguez‑Manzano is a co‑founder and CSO officer of PDx. He received a BSc in Biological Sciences, an MSc in Advanced Microbiology and a PhD in Biotechnology and Environmental Microbiology from the University of Barcelona. After post‑doctoral positions in the Division of Chemistry and Chemical Engineering at the California Institute of Technology (Caltech) and in the Department of Electrical and Electronic Engineering at Imperial College London, he moved to the Department of Infectious Disease as a non‑clinical Lecturer in Antimicrobial Resistance and Infectious Diseases in the Faculty of Medicine. Dr Rodriguez Manzano has a strong interdisciplinary background in microbiology, molecular biology and bioengineering, and his research interest includes the development of point‑of‑care technologies and novel molecular methods for diagnosis of infectious diseases and antimicrobial resistance, with particular interest in low‑ and middle‑income countries. He is the author of over 60 scientific publications and 10 international patent applications with over 2,000 citations.

Dr. Nicolas Moser is a co‑founder and CTO of PDx. He earned an MSc at Imperial College London with distinction and received the Hertha Ayrton Centenary Prize (best MSc project) and the MSc Analogue and Digital Integrated Circuit Design Outstanding Achievement Prize (highest ranking MSc student). He was awarded an EPSRC PhD Scholarship with the High Performance Embedded and Distributed Systems (HiPEDS) Centre for Doctoral Training (CDT) and pursued a PhD at the Centre for Bio‑Inspired Technology, Imperial College London, where he developed new methods for microchip‑based ion imaging. At the end of his PhD, he was awarded the EPSRC postdoctoral fellowship to pursue point‑of‑care devices towards rapid diagnosis of infectious diseases. He has pursued several entrepreneurial programmes including the Imperial College Techcelerate programme and the MedTech SuperConnector. He received the best poster at the All‑You‑Can‑Innovate conference and the CASS COVID‑19 Entrepreneur Award. He is the author of 39 publications and 2 patents.

An internationally acknowledged spine and scoliosis surgeon, successful investor and entrepreneur, Dr. Antonacci is board certified by the American Board of Orthopedic Surgery, a diplomate of the National Board of Medical Examiners, Fellow of the American Academy of Orthopedic Surgery, Fellow of the American College of Surgeons, Fellow of the Scoliosis Research Society, Fellow of the Cervical Spine Research Society and active member of the North American Spine Society.

Dr. Antonacci has extensive surgical experience in adults and children with spinal scoliosis. He is the developer and pioneer of anterior scoliosis correction (ASC) surgery for scoliosis, the most advanced surgical treatment for correcting scoliosis. ASC replaces metal rod fusion surgery and gives the patient the ability to continue with full sports, active life and flexibility in under two months.

Dr Antonacci graduated with a BS from Georgetown University before studying for MD in its School of Medicine. He has a residency in Orthopaedic Surgery at Baylor College of Medicine and a Fellowship at the Spinal Surgery at Jackson Memorial Hospital and is Lead Surgeon and Founder at the Institute Spine & Scoliosis.

Daniel Gratiot is a creative design and branding professional with over 30 years experience leading global design teams, driving innovation, and creating IPR for leading brands and start‑ups. Dan brings a holistic approach informed by consumer insights. Dan’s experience led work delivers relevant strategic innovation, with a strong customer focus. His diverse experience includes medical diagnostic instrumentation, consumer products, and telecoms. Creative innovation and leadership roles include Advanced Design UX at Microsoft, Nseries and Premium Design at Nokia, head of retail design at Swatch, as well as leading his own design consultancy. Dan Gratiot also worked for Ciba Corning Diagnostics, developing critical care blood gas analysers and single‑use point‑of‑care test systems

Roderick Rhys Jones is an engineer, entrepreneur, marketing professional, writer and charity director. He has been closely involved for many years in the transfer of technology from research. After graduating from Imperial College in engineering he joined the British Antarctic Survey to make the first maps of remote mountains from the Antarctic Base of Halley Bay. He traveled through South and North America working as a journalist and teacher before crossing the Pacific in a small yacht. On returning to London he worked as a business journalist and magazine editor before founding a marketing consultancy to serve the engineering and construction community internationally. In 2002 he set up a new department for fundraising and alumni relations at Imperial College. He reinvigorated Friends of Imperial College founding a charity to provide science lectures for the public and is now Chair Emeritus. He served on the Court of Imperial College for a number of years and was awarded the Imperial College Gold Medal for services to the College. He is Chair of the British Antarctic Monument Trust, a charity he set up to commemorate those men and women who lost their lives in British Antarctic Territory in the pursuit of science. He is a Fellow of the Royal Geographic Society, Fellow of the Royal Society of Arts and a Member of the Chartered Institute of Marketing.

Jaana Tarma brings to ProtonDx service design expertise, alongside her business acumen. At ProtonDx she is particularly interested in developing seamless processes, so that new medical innovations can be taken into use safely with minimal training. Her past roles include projects in health, wellness, sport and domiciliary and social care industries, both in the private and public sector. Her portfolio covers innovation projects, service development, lobbying, commercial expansion, stakeholder relationship building for organisations including the Ministry of Health and Social Affairs; the Ministry of Industry and Commerce; the Royal College of Art, sports heart rate monitor company Polar Electro; and domiciliary care provider Coviva. She teaches at universities in the UK, Finland and Chile, and has advised the government in European stakeholder engagement. She has a long experience in commercial strategy, including hands‑on roles in business development and international sales and marketing. Jaana is a CEO of her own business strategy and service design consultancy. She has a Masters degree in Economics and Business Management from Aalto University in Finland, and a Masters in Service Design from the Royal College of Art

Andrew Webb’s role at ProtonDx leverages over 30 years of commercial experience in the diagnostics and life Sciences industry. He is currently CEO at Extruded Pharmaceuticals prior to which he was Chief Commercial Officer at Novel Technologies Holdings. Before then he was Chief Executive Officer and founder of EKF Molecular Diagnostics and a NED at Arcis Biotechnology. Previously Senior Director at Qiagen following the acquisition of DxS where he was Commercial Director. Andrew Webb has also worked at Amersham/GE Healthcare following 5 years in pre‑clinical research at GlaxoSmithKline.